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ABSTRACT
Objectives: To examine the accuracy of a commercial polymerase chain reaction (PCR) test (Am-
plicor CTR, Roche Diagnostic Systems, Branchburg NJ) for identification of endocervical chla-
mydial infections through both laboratory evaluation and among a diverse teaching hospital patient
population.
Methods: Testing of reliable threshold inocula and reproducibility were carried out using labo-
ratory stock organisms. Paired endocervical samples from patients with a wide range of indications
were tested by PCR and an established culture procedure, and discrepant pairs were further
analyzed to determine true results.
Results: Laboratory evaluation suggested that one copy of target DNA from a viable organism
consistently yielded a positive result, and test reproducibility was very good, with an overall coef-
ficient of variation of 15%. Compared to true results in 1,588 paired clinical samples from 1,489
women with a 10% prevalence of infection, the PCR test and culture yielded respective sensitivities
of 87.4% and 78.0%, and negative predictive values of 98.6% and 97.6%. Specificity and positive
predictive value for both tests were 100%. Cost per specimen was nearly identical at $18.84 and
$18.88 respectively. Polymerase inhibitors and organisms lacking target DNA were not found in
false-negative PCR samples.
Conclusion: This commercial PCR test is accurate, cost-competitive, and much faster than cul-
ture for diagnosis of endocervical chlamydia infections in our population of intermediate prevalence
of chlamydial infection. Infect. Dis. Obstet. Gynecol. 6:224-229, 1998. (C) 1998 Wiley-Liss, Inc.
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trachomatis, serovars D-K, is widely
elieved to be the most common sexually
transmitted bacterial pathogen in the United
States. Reporting of these infections began in 1995,
revealing only about 500,000 cases annually, but
compliance with reporting (particularly among
men) is felt to be quite limited. Estimates of 3-4
million cases per year are probably more represen-
tative, z Further, reproductive morbidity arising
from genital chlamydial infection exceeds that of
any other cause of infertility,
3 ectopic pregnancy,4
pelvic inflammatory disease,s and neonatal pneu-
monia,6 and it is an important contributor to ad-
verse pregnancy outcome7 and failure of assisted
reproduction,s Diagnosis of genital chlamydial in-
fection has been problematic. The majority of af-
fected women are asymptomatic and thus do not
seek testing. Epidemiologic paradigms to identify
those who should be tested have been ineffectual,9
with the exception of annual screening of all sexu-
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ally active adolescent and young adult women,
which is highly effective. 1,11 These serovars are
poor antigens, so serodiagnosis has not been help-
ful. Identification of the organism by more afford-
able tests such as enzyme immunoassay, lz direct
fluorescent antibody staining,
13 Pap test,4 and
DNA probes 15 is relatively insensitive. Culture of
the organism is slow, labor intensive, and expen-
sive but has traditionally been taken as the gold
standard for laboratory diagnosis of genital chla-
mydial infection. Recently, DNA amplification
tests have emerged as competitors for the preferred
method for diagnosis. Given the value of broadly
based screening for prevention of genital chlamyd-
ial infection and its complications as recommended
by the Centers for Disease Control and Prevention
(CDC),6 extensive information on the perfor-
mance of various laboratory tests for C. trachomatis
in geographically and culturally diverse settings is
important. We therefore undertook this study to
determine the relative accuracy of culture and
polymerase chain reaction (PCR)-based testing
among our southeastern U.S., hospital-based pa-
tient population where chlamydial infections are of
intermediate prevalence.
SUBJECTS AND METHODS
Laboratory evaluation of PCR testing for C. tracho-
marls was undertaken prior to initiation of clinical
testing. Using dilutions of low-titer positive control
stock employed in our culture system (C. trachoma-
tis serovar E), we calculated the threshold number
of target DNA copies needed to consistently yield
a positive PCR result. Further, we assessed the
reproducibility of the test in our hands among dif-
ferent assays by repetitive testing of a sample that
gave results in the quantifiable range of the test,
absorbance 0 to 3, in accord with the NCCLS
EP5T guideline.
From October 1996 to April 1997, unselected
women attending obstetric, gynecologic, and emer-
gency clinics at our institution for whom testing for
genital chlamydia was felt by their clinicians to be
indicated were candidates for this study. Indica-
tions included pelvic pain, cervicitis, presence of
other STD, risk factors for STD, symptomatic part-
ner, new obstetric patient screening, asymptomatic
sexually active adolescents and young adults, and
others. No characteristic excluded patients from
participation, and samples were excluded from
analysis only if they were not endocervical swab-
bings or if they were rejected for reasons of im-
proper transport or identification. Chlamydia speci-
mens were obtained after all other endocervical
samples were taken. The culture specimen was
taken first, rotating a Dacron-tipped, plastic stick
swab in the endocervical canal and transporting it
in 2M sucrose-phosphate medium at 4C to the
laboratory within 24 hr. The PCR specimen was
then taken using the same technique; the swab was
rotated and squeezed out in the manufacturer’s
transport medium and discarded. The transport
medium was held at room temperature or refriger-
ated before delivery to the laboratory within 24 hr
for processing. Verbal consent was obtained from
each patient for the additional endocervical swab-
bing, as approved by our institutional review board.
Results ofPCR testing were in no case made avail-
able outside the laboratory.
The PCR test used, Amplicor CT(R) (Roche Di-
agnostic Systems, Branchburg, NJ) was carried out
according to the manufacturer’s procedure by per-
sonnel who had successfully completed the stan-
dard three-day training course offered by the
manufacturer. Briefly, the test employs biotinyl-
ated primers targeting a highly conserved 207 base
pair segment in the genome of a cryptic plasmid
found exclusively in all serotypes of C. trachomatis.
In the presence of thermostable polymerase and
deoxyribonucleotide triphosphates, thermocycling
reproduces each copy of target DNA to (in theory)
109 copies after 30 cycles. Copies are then bound,
excess reagent washed out, and avidin-peroxidase
added. Biotinylated target DNA in the sample
binds the avidin, and colorimetric changes induced
by peroxidase, measured spectrophotometrically at
450A, signify the presence of target DNA. A nu-
ance of this system is the addition of uracil N-
glycosylase, which destroys amplified DNA under
ambient conditions, thus minimizing the risk of
contamination of other specimens in the laboratory.
All specimens were assayed in duplicate. If absor-
bance results in both aliquots was ->0.5, the speci-
men was positive for C. trachomatis; if <0.2, nega-
tive. If either aliquot fell in the range ->0.2 to < 0.5,
the specimen was assayed again in triplicate and
reported as positive if three or more of the five
results was ->0.25, negative if three or more were <
0.25. Our culture technique has been previously
reported. 17,18 Briefly, shell vials containing a coy-
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erslip with a monolayer ofMcCoy cells were inocu-
lated in duplicate with clinical specimen by cen-
trifugation at 1,700g at 35 C for 1 hr, then incu-
bated at 35 C in 5% COz for 64-68 hours in
medium containing cycloheximide to suppress cel-
lular activity. One of the aliquots was then blindly
subcultured to another monolayer, which was then
treated identically to the primary culture sequence.
The other coverslip was stained with iodine and
examined at 400 magnification for cellular inclu-
sions of C. trachomatis. A positive resul consisted of
one or more typical inclusions in the primary or
passage culture. Equivocal specimens and those
with few inclusions were independently evaluated
by two experienced observers, and both must have
interpreted it as positive for a final positive result to
be assigned. If either observer interpreted a speci-
men as negative or if no typical inclusions were
seen, a negative result was issued.
Discrepancy analysis followed predetermined
rules. For all discrepant pairs, culture and the plas-
mid-target PCR test were repeated. In addition,
among the first 600 samples, PCR using primers
targeting DNA coding for the major outer mem-
brane protein (MOMP)of C. trachomatis was con-
ducted. Results of the plasmid-target and MOMP-
target PCR tests agreed in every case, so MOMP-
target PCR testing was discontinued for the
balance of the study. True-positive samples were
defined as those that were: 1) culture-positive and
PCR-positive on initial testing, 2) culture-positive
and PCR-negative on initial testing, and 3) culture-
negative and PCR-positive on initial testing and
positive by repeat culture or PCR testing. Thus, all
samples with a positive culture were taken as true-
positive regardless of PCR result. True-negative
samples were defined as those that were: 1) cul-
ture-negative and PCR-negative on initial testing
and 2) culture-negative and PCR-positive on initial
testing and negative by repeat culture and PCR
testing.
Available PCR specimens from culture-positive,
PCR-negative pairs were tested for the presence of
polymerase inhibitors by repeat PCR testing of the
specimen after "spiking" it with a low-titer posi-
tive control standard--a negative result from this
mixture indicates the presence of polymerase in-
hibitors in the specimen. Test cost analysis was
undertaken by evaluation of direct expenses over a
six-month interval for reagents, supplies, and ma-
TABLE I. Results of reproducibility testing of
PCR-based detection of C. trachomatis
Negative Positive
Sample control test sample
Number of replicates assayed 80 80
Replicates in expected range (%) 100 100
Mean absorbance 0.051 1.446
Standard deviation
Within-run 0.0010 0.1212
Between-run 0.0005 0.2667
Between-day 0.0012 0
Total 0.0016 0.2182
Coefficient of variation (%)
Within-run 1.94 8.25
Between-run 1.01 18.16
Between-day 2.40 0
Total 3.19 15.09
aSee text for definition of sample.
terials used in the performance of each test; amor-
tized cost of equipment based on manufacturer’s
estimate of life span; and the assumption that one
FTE for culture and 0.8 FTE for PCR for a senior
technologist were required. Indirect costs such as
physical plant, quality control, and administration
were not included. The costs were then divided by
the number of specimens assayed during the inter-
val. Our laboratory typically processes about 5,000
specimens annually.
The McNemar statistical test was used to com-
pare test results with statistical significance set at
P < 0.05.
RESULTS
Positive threshold evaluation of the PCR test em-
ployed the low-titer control used in our culture sys-
tem, which over the years has reliably produced a
mean of 3.6 inclusion-forming units/100 pL
sample. Through trial and error we found that 1:24
was the greatest dilution of this stock which con-
sistently produced a positive result in the PCR test,
which employs a 50-pL sample. It is known that
each viable C. trachomatis organism contains about
10 copies of target DNA. Thus, we calculate that
approximately one copy of target DNA is needed
to consistently yield a positive PCR result (3.6 10
0.5/24). Reproducibility testing employed that
1:24 dilution of stock positive control, and those
results are shown in Table 1.
Results from culture and PCR testing were
available from 1,588 paired endocervical samples
from 1,489 women. Table 2 shows the demograph-
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TABLE 2. Demographic characteristics of patients
providing specimens for evaluation of PCR-based
testing for C. trachomatis
Age (mean yrs. + SD) 28.7 + 9.3
Race
Black 1,009 (67.8%)
White 363 (24.4%)
Other/unknown II 7 (7.7%)
Marital status
Single 1,000 (67.2%)
Married 309 (20.8%)
Unknown 180(I 1.9%)
TABLE 3. Outcome of initial testing for
C. trachomatis by culture and PCR in 1,588
paired samples*
Culture
PCR Positive Negative
Positive 104 35
(6.5%) (2.2%)
Negative 20 1,429
(I.3%) (90.0%)
*P < 0.01 (McNemar test).
ics of the group. Table 3 shows the correlation of
initial culture and PCR testing. Results of discrep-
ancy resolution testing of all culture-negative/PCR-
positive pairs is shown in Table 4, along with the
retesting done for culture-positive/PCR-negative
pairs, which was limited because our protocol pre-
determined that all culture-positive samples were
true-positive. Finally, initial results of each test
were compared with true results determined by
discrepancy resolution. (Table 5).
None of nine PCR specimens from PCR-
negative/culture-positive pairs showed evidence of
polymerase inhibitors. Cost per specimen analysis
for the two tests showed remarkable similarity in
our laboratory. A typical PCR test cost $9.37 for
materials and $9.47 for labor (total, $18.84). The
corresponding figures for culture were $4.30 and
$14.58 (total, $18.88), respectively.
DISCUSSION
Our calculation that one copy of target DNA in the
specimen will consistently produce a positive result
in the Amplicor CT test is in keeping with the
mechanisms ofPCR technology. However, the cal-
culation assumes the presence ofDNA from viable
organisms only. The proportion of target DNA in
our specimen derived from viable organisms is not
known but should be high based on the procedures
used to prepare our stock, which exclude cell de-
bris. Because each viable organism in a clinical
specimen carries 10 copies of target DNA, we are
comfortable that a single organism will yield a posi-
tive PCR test under proper conditions. Our repro-
ducibility testing shows excellent consistency of
the test and is comparable to results provided by
the manufacturer. It should be noted, however,
that reproducibiity of this test among a subset of
samples with equivocal results has recently been
called into question. 19
TABLE 4. Results of discrepancy resolution testing
in the comparison of culture and PCR-based testing
for C. trachomatis
Culture-negative/ Culture-positive/
Initial test PCR-positive PCR-negative
results Positive Negative Positive Negative
Repeat culture I/I 10/I I/8 7/8
Repeat plasmid-
primer PCR 35/35 0/35 2/8 6/8
MOMP-primer
PCR 13/I 3 0/I 3 2/8 6/8
TABLE 5. Performance of culture and PCR-based
testing compared to true results determined by
discrepancy resolution
True positive True negative
(n 159) (n 1429)
PCR positive 139 (87.4%) 0
PCR negative 20 (12.6%) 1429 (100%)
Culture positive 124 (78.0%) 0
Culture negative 35 (22%) 1429 (100%)
The population of women we studied is a mix-
ture of high-risk patients and those at lower risk
who were subject to screening protocols. This mix-
ture is typical of hospital-based practices. Addi-
tional data on patient characteristics were not pro-
spectively collected, as they apparently have little
significance with regard to risk for chlamydia geni-
tal infection,9 and no data suggest that they impact
test accuracy. The prevalence of cervical infection
by C. trachomatis in our population was 10%, inter-
mediate between private office practices and STD
clinics. The PCR-based test performed very well in
this setting, with results of initial testing in agree-
ment with our established culture technique in
96.5% of specimen pairs. Further, after identifica-
tion of true results for each specimen by discrep-
ancy analysis, the PCR test yielded sensitivity of
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87.4%, specificity of 100%, and negative- and posi-
tive-predictive values of 98.6% and 100% ,respec-
tively. The corresponding values for culture were
78.0%, 100%, 97.6%, and 100%. These values, in-
cluding the trend toward better sensitivity with
PCR than culture, are comparable to those found in
other studies that also employed high-quality cul-
ture techniques,z-z3
We feel that our decision to count all culture-
positive pairs as true-positive is well founded. This
approach was also used by Bauwens et al.z4 Loef-
felholz et al. el found all of 113 culture-positive/
PCR-negative pairs to be true-positive after dis-
crepancy resolution, as did Bass et al.z among all of
74 such samples. Further, we applied very strin-
gent criteria for interpretation of a positive culture
result. We use iodine stain which enhances test
specificitynprobably at the cost of sensitivityzs---
when compared to fluorescent antibody stain, be-
cause it provides for evaluation of inclusion mor-
phology. Using criteria recommended by the
CDC, 18 two experienced observers were required
to conclude independently that inclusion location,
color, granularity, peripheral clearing, and nuclear
indentation were all appropriate for a positive re-
sult.
Moreover, as discussed by Green et al.,z6 the
bias associated with discrepancy analysis-based es-
timates of PCR test sensitivity is minimized by
assigning high specificity to culture results. We
were not surprised that reculture of specimens
from culture-positive discrepant pairs was often
negative, as all of them showed low-titer infectivity
initially, and the detrimental effect of an additional
freeze-thaw cycle on inclusion count is well
known, z7 We believe the insensitivity of direct
fluorescent antibody stain and enzyme immunoas-
say tests make them inappropriate for use in re-
solving disagreement between culture and PCR-
based tests. Ligase chain reaction testing was not
available to us at the time of this study.
Inhibitors of the PCR process have been de-
scribed in cervical specimens at a frequency of 19%
by Verkooyen et al.,z8 using the method of detec-
tion we used. Using more sophisticated methods,
Bass et al.z found inhibitors in 4% of their speci-
mens. We found no evidence of PCR inhibitors in
the nine culture-positive/PCR-negative samples
we tested. C. trachomatis lacking the cryptic plas-
mid which contains the DNA targeted by Amplicor
CT has been described, z9 All eight culture-
positive/plasmid PCR-negative samples we tested
were also negative by PCR testing with primers for
MOMP DNA, indicating that chlamydia lacking
plasmids was not the explanation for false-negative
PCR results in these specimens. Our culture-
positive/PCR-negative specimens may have re-
sulted from improper specimen procurement,
transport, or processing. We did not monitor the
adherence of clinicians to the specimen procure-
ment procedure. Specimen adequacy has been
shown to be an important determinant of the sen-
sitivity of this test.3 We were unable to assess this
factor because of cytolytic agents included in the
transport medium.
Our study suggests that the Amplicor CT PCR-
based test for endocervical C. trachomatis infection
offers accuracy at least equivalent to culture at the
same cost, and provides results much more rapidly,
in a large population with intermediate prevalence
of infection. Where resources provide for it, this
PCR test may be the preferred method for labora-
tory diagnosis of endocervical chlamydial infec-
tions.
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